Rene Lenggenhager is announced Biospin group president

Bruker today announces the appointment of Dr. Rene Lenggenhager as President of the Bruker BioSpin Group, effective November 1st, 2015.  Rene has over 25 years of management experience in international high-tech companies and in the scientific instruments industry, where his responsibilities have included general management with P&L responsibility for a global business, marketing, R&D and global operations.  Rene has extensive experience with complex transformations, operational excellence, lean manufacturing, marketing and value selling.  Moreover, Rene has a very successful track record in sustainable, profitable growth with a focus on customers and innovation.

Rene Lenggenhager

Since 2004, Dr. Lenggenhager has served as General Manager for Laboratory Weighing at Mettler Toledo (MTD).  From 2000 until 2003, he was the Head of R&D of Laboratory & Weighing Technologies at MTD.  Previously, he worked at the Siemens Building Technologies SBT Cerberus Division, at Cerberus AG, at Landis & Gyr AG and at Metrohm AG.  Rene holds a Ph.D. in physics from the Swiss Federal Institute of Technology (ETH), Zurich, a Bachelor of Science in electronics from the University of Applied Sciences NTB, Buchs, and an Executive MBA from University of St. Gallen, all in Switzerland.

Frank Laukien, President and CEO of Bruker Corporation, said:

I am very pleased to welcome Rene to Bruker.  His success in our industry, his broad technical background, and his passion for innovation and customers are impressive.  His outstanding track record with operational excellence, profitable growth and margin enhancement make René a compelling Group President to lead Bruker BioSpin to the next level.”

Dr. Rene Lenggenhager commented: “Bruker has a strong reputation for excellence in the customer community, with high-performance instruments and high-value analytical solutions.  Bruker BioSpin is making progress with its transformation and recent new product launches, and I am excited to join this creative team to drive profitable growth and value for our customers and shareholders.  I am committed to business success and to providing the best solutions to make our customers successful, and to develop new applications that will improve the quality of human life.”

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New cell therapy offers effective treatment for patients with T-cell acute lymphoblastic leukemia